Tumor risk biomarkers and physical activity in type 2 diabetes, patients with colorectal cancer and individuals without diabetes
| Autor: | Joachim Wiskemann, Gerhard Huber, Hubert Allgayer, Robert W. Owen, Hermann Brenner, Cornelia M. Ulrich, Ulrike Bussas, Karen Steindorf |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Oncology
medicine.medical_specialty business.industry Colorectal cancer Physical activity Endocrinology Diabetes and Metabolism Urinary system Alpha (ethology) Type 2 diabetes medicine.disease RC648-665 8-oxo-2’ Deoxyguanosine Diseases of the endocrine glands. Clinical endocrinology Excretion Endocrinology Prostaglandin E2alpha and metabolites Diabetes mellitus Internal medicine medicine Biomarker (medicine) Prostaglandin E2 business medicine.drug |
| Zdroj: | Endocrine and Metabolic Science, Vol 3, Iss, Pp 100091-(2021) |
| ISSN: | 2666-3961 |
| Popis: | Biomarkers such as 8-oxo-2’deoxy-guanosine (8-oxo-dG), prostaglandin E2 alpha (PGE2 alpha), prostaglandin metabolites (PGEM) and 8-isoprostane (8-iso) may quantitatively reflect individual tumor risk including colorectal cancer (CRC) and may be useful in clinical management and prevention programs. To further clarify their role in a clinical setting we compared urinary excretion levels with regard to physical activity and other clinical and metabolic parameters in patients with longstanding (>5 years) type 2 diabetes (T2D) (moderate risk) and in those with curatively treated CRC (high risk for recurrence). Patients and methods: In this one center case-control study 60 patients with T2D and 40 patients with CRC were compared with 40 healthy controls. Levels of physical activity were assessed in MET-hr/wk. Urinary excretion of 8-oxo-dG, PGE2 alpha, PGEM and 8-iso were determined by HPLC-ESI mass-spectrometry and ELISA, respectively. Results: Urinary 8-oxo-dG excretion was 33.7% higher in T2D compared to controls (P=0.01), in CRC excretion was 83.6% higher (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|